Clearside Biomedical, Inc.

NasdaqGM:CLSD 주식 보고서

시가총액: US$97.2m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clearside Biomedical 관리

관리 기준 확인 2/4

Clearside Biomedical's CEO는 George Lasezkay, Apr2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 $ 1.54M, 35.6% 로 구성됩니다. 35.6% 급여 및 64.4% 보너스(회사 주식 및 옵션 포함). 는 $ 428.70K 가치에 해당하는 회사 주식의 0.51% 직접 소유합니다. 428.70K. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 5 년입니다.

주요 정보

George Lasezkay

최고 경영자

US$1.5m

총 보상

CEO 급여 비율35.6%
CEO 임기5.2yrs
CEO 소유권0.5%
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간5yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Clearside Biomedical's early-stage wet AMD study gets underway

Jan 12

Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares

Jan 12
Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares

Clearside Bio drops 11% on launch of $12M direct offering

Jan 06

Clearside Biomedical: SCS Microinjector Platform With Significant Upside

Jan 05

CEO 보상 분석

George Lasezkay 의 보수는 Clearside Biomedical 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$35m

Dec 31 2023US$2mUS$547k

-US$32m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$36m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$532k

-US$33m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

US$83k

Dec 31 2021US$2mUS$516k

US$376k

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$1mUS$503k

-US$18m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$385k

-US$31m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$82m

Dec 31 2018US$150kn/a

-US$83m

Sep 30 2018n/an/a

-US$78m

Jun 30 2018n/an/a

-US$72m

Mar 31 2018n/an/a

-US$65m

Dec 31 2017US$167kn/a

-US$59m

보상 대 시장: George 의 총 보상 ($USD 1.54M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 George 의 보상이 증가했습니다.

CEO

George Lasezkay (72 yo)

5.2yrs

테뉴어

US$1,538,627

보상

Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...

리더십 팀

이름위치테뉴어보상소유권
George Lasezkay
President5.2yrsUS$1.54m0.51%
$ 497.6k
Charles Deignan
Chief Financial Officer12.4yrsUS$854.41k0.45%
$ 438.7k
Thomas Ciulla
Chairman of Scientific Advisory Board5.7yrsUS$749.87k0%
$ 0
Jenny Kobin
Head of Investor Relationsno data데이터 없음데이터 없음
Rick McElheny
Senior Vice President of Corporate Development & Alliance Management1.8yrs데이터 없음데이터 없음
Rafael Andino
Senior Vice President of Engineering & Manufacturing1.4yrs데이터 없음데이터 없음
Susan Coultas
Chief Clinical Officer2yrs데이터 없음데이터 없음
Ngai Hang Chong
Chief Medical Officerless than a year데이터 없음0.085%
$ 82.5k
Leslie Zacks
Secretaryno data데이터 없음데이터 없음

2.0yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: CLSD 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
George Lasezkay
President6.8yrsUS$1.54m0.51%
$ 497.6k
Thomas Ciulla
Chairman of Scientific Advisory Board1.3yrsUS$749.87k0%
$ 0
Christy Shaffer
Independent Director12.4yrsUS$86.08k0.0059%
$ 5.7k
Benjamin Yerxa
Independent Director2.3yrsUS$88.58k0.024%
$ 23.3k
Jeffrey Edwards
Independent Director5.8yrsUS$88.58k0%
$ 0
Clay Thorp
Independent Chair of the Board12.4yrsUS$96.08k0.054%
$ 52.7k
Carl Regillo
Member of Scientific Advisory Board4.2yrs데이터 없음데이터 없음
William Humphries
Independent Director12.4yrsUS$91.71k0.068%
$ 66.4k
David Boyer
Member of Scientific Advisory Board4.2yrs데이터 없음데이터 없음
Nancy Hutson
Independent Director4.2yrsUS$85.46k0.12%
$ 120.9k
Richard Croarkin
Independent Director8.3yrsUS$91.08k0%
$ 0
David Brown
Member of Scientific Advisory Board4.2yrs데이터 없음데이터 없음

5.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: CLSD 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.